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ABSTRACT: The Hippo pathway is an important regulator of cell growth,
proliferation, and migration. TEAD transcription factors, which lie at the core of
the Hippo pathway, are essential for regulation of organ growth and wound
repair. Dysregulation of TEAD and its regulatory cofactor Yes-associated protein
(YAP) have been implicated in numerous human cancers and hyperproliferative
pathological processes. Hence, the YAP−TEAD complex is a promising
therapeutic target. Here, we use in silico molecular docking using Bristol
University Docking Engine to screen a library of more than 8 million druglike
molecules for novel disrupters of the YAP−TEAD interaction. We report the
identiﬁcation of a novel compound (CPD3.1) with the ability to disrupt YAP−
TEAD protein−protein interaction and inhibit TEAD activity, cell proliferation,
and cell migration. The YAP−TEAD complex is a viable drug target, and
CPD3.1 is a lead compound for the development of more potent TEAD
inhibitors for treating cancer and other hyperproliferative pathologies.
■ INTRODUCTION
The oncogenic Hippo signaling pathway has emerged as an
important regulator of cell growth,1 proliferation,2 and
migration.3 TEAD transcription factors (TEAD1−4), at the
core of the Hippo pathway, are essential for regulation of
normal organ size, cardiogenesis,4 formation of the trophecto-
derm5 in embryos, and wound repair in adults.3 Dysregulation
of TEAD proteins has been implicated in numerous human
cancers, including breast cancers,6 fallopian tube carcinoma,7
germ cell tumors,8 renal cell carcinoma,9 medulloblastoma,10
and gastric cancer.11 Increased TEAD activity can induce
oncogenic transformation.12−14 Moreover, increased TEAD
protein expression in gastric,15 colorectal,16 breast,6 and
prostate cancers17 is associated with reduced patient survival.
Dysregulated TEAD activity has also been associated with
other hyperproliferative pathological processes, including
angioplasty restenosis.18
Transcriptional activation by TEAD is dependent on
interaction with transcriptional cofactors. The best charac-
terized TEAD cofactors are Yes-associated protein (YAP) and
transcriptional coactivator with PDZ-binding motif (TAZ).19
However, other proteins have also been reported to have
TEAD cofactor activity, including members of the Vgll
family20−22 and p160 family of nuclear receptor cofactors.23
The activity of YAP and TAZ is negatively regulated by the
Hippo pathway kinase LATS1,24−27 which can occur in
response to actin cytoskeleton disruption. Phosphorylation of
YAP and TAZ triggers their nuclear export and proteasomal
degradation. Although YAP and TAZ appear to be dispensable
for normal homeostasis of many adult organs,28 they play
essential roles promoting tissue repair following injury.29,30 As
with the TEAD proteins, YAP and TAZ activation has been
identiﬁed in many human tumors and is essential for tumor
initiation, progression, and metastasis.31 Furthermore, elevated
expression of YAP is associated with reduced survival in
patients with breast,32 ovarian,33 colon,34 liver,35 and
pancreatic36 cancers. Consistent with this, the activation or
overexpression of YAP or TAZ enhances TEAD-dependent
gene expression (e.g., CCN1, CTGF, ITGB2, and Birc5/
Survivin) and promotes cell proliferation and migration in
many cell types.37 Conversely, signals or interventions that
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block the formation of YAP/TAZ−TEAD complexes prevent
the expression of many mitogenic TEAD target genes and
dramatically reduce cell proliferation and oncogenic trans-
forming activity.37−40
Figure 1. BUDE screening-identiﬁed compound 3 for TEAD inhibition. (A) HeLa cells were stably transduced with a lentiviral viral vector
containing 8×TEAD-secreted nanoluciferase reporter gene (TEAD-NLUC). Cells were transfected with non-targeting siRNA (siNEG), siRNA
targeting YAP (siYAP), control adenoviral vector or an adenovirus expression constitutively active YAPS127A (Ad:YAP). Culture media were
conditioned for 6 h and assayed for secreted nanoluciferase activity (n = 3). (B) HeLa cells stably transduced with TEAD-NLUC were treated with
100 μM of indicated compound for 6 h. Cell conditioned media were assayed for nanoluciferase activity (n = 3). (C) Chemical structure of
compounds that statistically signiﬁcantly inhibited TEAD-NLUC activity. (D) Recombinant GST-TEAD1 protein bound to glutathione resin was
incubated with 200 μM of the indicated compounds and HEK293 cell lysate containing endogenous YAP protein for 18 h at 4 °C. The resin was
washed, and bound YAP eluted and quantiﬁed by Western blotting (n = 2). (E and F) HeLa cells were transfected with myc-TEAD1 or GFP-YAP
plasmids and total cell lysates prepared. Myc-TEAD lysates incubated with 200 μM of CPD3 for 3 h before addition of GFP-YAP lysate. Myc-
TEAD:GFP-YAP complexes were co-immunoprecipitated with either GFP-Trap (E; n = 3) or myc-TRAP (F; n = 3). Co-immunoprecipitated YAP
or TEAD was quantiﬁed by Western blotting. Schematic illustration of 96 well plate YAP-TEAD interaction assay (G). Dose response analysis of
disruption YAP-NL interaction with myc-TEAD by CPD3.1 (H). * = p < 0.05, ** = p < 0.01, *** = p < 0.001.
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Multiple and diverse signals induce nuclear translocation of
YAP and TAZ, including cellular density GPCR ligands,41
mitogens,42 Wnts,43 and extracellular matrix stiﬀness.44
Conversely, multiple antimitogenic signals induce nuclear
exclusion of YAP and TAZ and inhibition of TEAD-dependent
gene expression.39,45 This suggests that the YAP/TAZ−TEAD
complex acts as a central point of convergence for multiple
biochemical and mechanical signaling pathways that control
cell proliferation and migration. Hence, there is considerable
interest in targeting these proteins therapeutically, for example,
for the treatment of cancer,46 cardiovascular disease,39 and
liver ﬁbrosis.47 Targeting the Hippo pathway would be distinct
from conventional cytotoxic chemotherapy or medications that
lower low-density lipoprotein cholesterol, the current main-
stays of cancer and cardiovascular disease treatment that,
nevertheless, do not fully normalize risk. These multifactorial
pathologies are characterized by dysregulation of multiple
diverse signaling pathways that converge at a relatively small
number of transcription factors, suggesting that targeting
transcription factors may represent a highly promising, widely
applicable therapeutic strategy. However, pharmacological
targeting of transcription factors is challenging. Unlike
enzymes, they often lack deep binding pockets for small
molecules and instead rely on complex protein−protein
interactions based on large surface areas, which are tradition-
ally believed to be more diﬃcult to target.48
Small molecules with YAP−TEAD inhibitory properties
have been reported. For example, the TEAD inhibitory activity
of the porphyrin molecule, verteporﬁn, was identiﬁed by
screening a library of 3300 Food and Drug Administration-
approved drugs.14,40 Verteporﬁn inhibits YAP, at least in part,
by stimulating levels of 14-3-3ε, which sequesters YAP in the
cytoplasm.40 Moreover, verteporﬁn is pleiotropic, having
antiproliferative and cytotoxic eﬀects independent of its eﬀect
on YAP.27,49 Oku et al.50 identiﬁed dasatinib, ﬂuvastatin, and
pazopanib as inhibitors of YAP/TAZ nuclear localization using
image-based screening of 400 small molecules. Their
mechanisms of action are unclear but may be mediated via
inhibition of RhoA and disruption of actin polymerization.50
The recent elucidation of the crystal structure of the YAP−
TEAD1 complex51 (PDB accession code 3KYS) opens the
possibility of rationally designed direct YAP−TEAD inter-
action inhibitors. Crystallography indicates that YAP protein
wraps around the YAP-binding domain of TEAD1, forming
extensive interactions over three distinct interaction interfaces.
Structural and mutational studies identiﬁed a small number of
highly conserved amino acids, namely, Ser94, Phe95, and Phe96,
located in the Ω-loop of YAP, part of interaction interface
three, which are essential for YAP interaction with TEAD.51
The side chains of these residues ﬁt into a deep hydrophobic
pocket on TEAD that has an excellent druggability score,52,53
suggesting that the YAP−TEAD interaction may be a feasible
drug target. Consistent with this, two groups have reported the
design of peptides based on the YAP interaction interface with
the ability to disrupt YAP−TEAD interaction,54 albeit in a cell-
free system. Use of peptide-based interaction inhibitors is
limited by their poor cell permeability, with inhibition of
TEAD activity only achieved via plasmid-based expression of
FLAG-tagged peptide fusion proteins. Thermal-shift-assay-
based screening of a small molecule fragment library has
identiﬁed cell permeable small molecules that bind the TEAD
hydrophobic pocket occupied by YAP Phe95, but these
molecules exhibited low potency, modestly inhibiting TEAD
activity at millimolar concentrations.55
Here, we use in silico molecular docking using Bristol
University Docking Engine (BUDE)56,57 to screen more than 8
million clean (compounds with only benign functional
groups58) and druglike molecules from the Zinc Is Not
Commercial (ZINC) available compounds database for novel
disrupters of the YAP−TEAD interaction. In contrast to most
other docking algorithms, BUDE utilizes an empirical free-
energy force ﬁeld and is unique in using an atom−atom force
ﬁeld, which takes into account Wolfenden solvation energies.
This allows BUDE to more accurately estimate the entropic
cost/enthalpic gain encountered by a ligand, leaving a fully
solvated state to bind to a protein. This is particularly
important for interrogating the more challenging, ﬂatter
protein−protein or protein−ligand interactions because these
often rely more heavily on hydrophobic interactions. Here, we
describe a BUDE screening strategy that identiﬁed a shortlist
of putative TEAD1-binding compounds, from which we
characterize a novel compound that disrupts TEAD-dependent
transcription, cell proliferation, and cell migration.
■ RESULTS
Identiﬁcation of TEAD Inhibitors Using BUDE Molec-
ular Docking. The enrichment process from the ﬁrst BUDE
docking reduced the number of conformers from 160 million
to 100 000. The second BUDE run docked the 100 000
compounds into ﬁve structures extracted from the molecular
dynamics (MD) simulation of TEAD1 (to represent the
“breathing” motion of the unbound protein in solution and
allowed for both side-chain and backbone ﬂexibilities), which
allowed the selection of 1000 compounds showing binding to
at least four TEAD1 protein conformations (Supplement
Figures 1 and 2). The selection process from 1000 (see
Supplement Data File S1) to the ﬁnal list of 16 compounds
(Supplement Tables 1 and 3) for testing in vitro used the
following set of criteria: (i) visual inspection to identify
compounds that interacted with YAP binding pocket that
accommodates the epsilon two carbon atom of the YAP Phe95
residue (Supplement Figure 1); (ii) maximizing the chemical
diversity of the initial test set; (iii) favorable calculated (c Log
P) or experimental (log P) solubility; and (iv) actual
compound availability for purchase at a reasonable (<£200)
cost per screening sample.
The shortlisted sets of 16 compounds were ﬁrst assayed for
their ability to inhibit TEAD-dependent transcriptional activity
in HeLa cells that had been transduced with a recombinant
lentiviral vector expressing secreted bioluminescent nano-
luciferase (NLUC) reporter gene enzyme, which is expressed
under the control of a promoter region containing eight TEAD
DNA-binding elements (TEAD-NLUC). The reporter cell line
was validated by showing that the expression of secreted
nanoluciferase (NLUC) enzyme activity was signiﬁcantly
inhibited by siRNA-mediated silencing of the TEAD cofactor
YAP (Figure 1A). Furthermore, the expression of secreted
nanoluciferase (NLUC) enzyme activity was signiﬁcantly
stimulated by YAP overexpression (Figure 1A). These data
demonstrate that this cell line faithfully reports YAP-dependent
TEAD activity. Four of the compounds shortlisted (CPD1, 3,
6, and 8) signiﬁcantly (>60%) inhibited TEAD-NLUC activity
(Figure 1B,C), without signiﬁcantly aﬀecting cell viability
(Supplement Figure 3), indicating that these compounds
inhibited TEAD-dependent transcriptional activity.
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We next tested the ability of these four compounds to inhibit
the binding of endogenous YAP protein present in HEK293
whole cell lysate to recombinant glutathione S-transferase
(GST)−TEAD1 protein immobilized on glutathione resin
beads. Western blotting of proteins binding the beads
demonstrated that only CPD3 was able to inhibit the binding
of YAP protein to GST−TEAD1 (Figure 1D). Inhibition of
YAP binding to TEAD1 in the presence of CPD3 was further
conﬁrmed using co-immunoprecipitation assays using mamma-
lian cell lysates prepared from HeLa expressing myc-TEAD1
and GFP−YAP. CPD3 inhibited binding of myc-TEAD1 to
aﬃnity-puriﬁed GFP−YAP (Figure 1E). Likewise, CPD3 also
inhibited binding of GFP−YAP to immunoprecipitated myc-
TEAD1 (Figure 1F). We next set up a 96-well plate-based
YAP−TEAD interaction assay to determine the IC50 of the
inhibition of the YAP−TEAD complex by CPD3. Myc-tagged-
TEAD1 protein was immobilized on protein-G-coated plates
using an anti-myc antibody and the interaction of a YAP−
nanoluciferase fusion protein quantiﬁed in the presence of
increasing concentrations of CPD3 (Figure 1G). Incubation
with CPD3 resulted in a dose-dependent inhibition of YAP−
nanoluciferase activity bound to the myc-TEAD1 protein-
coated wells, indicating that CPD3 inhibited YAP interaction
with TEAD1. The IC50 of the inhibition was calculated at 48
μM (Figure 1H).
The BUDE docking pose of CPD3 (Figure 2A,B; see PDB
Data File) predicts that the planar indole-based aromatic ring
structure of CPD3 occupies the hydrophobic TEAD1 pocket
bordered by residues Leu272, Glu368, Glu393, and Try406
(residue numbering according to Li et al.51) in a vertical
orientation. The docking pose predicts that CPD3 binds in a
position close to the YAP Met86, Ile91, and Phe95 side chains
(numbering according to sequence NP_068780). These
hydrophobic side chains of YAP form multiple van der
Waals contacts with I247, V242, L272, V391, and Y406 of TEAD1
(numbering according to Li et al.51) and are known to be
essential for YAP binding.51 The furyl moiety at the opposite
end of the molecule occupies a cleft formed by TEAD1 Tyr376
and Asn411.
Compound 3 Inhibits TEAD-Dependent Target Gene
Expression, Cell Proliferation, and Migration. Activation
of TEAD transcription factors in response to YAP binding
induces the expression of many genes that encode proteins
known to be involved in promoting cell proliferation and
migration (see Supplement Figure 14). The best characterized
TEAD target genes associated with the promotion of cell
proliferation and migration are CCN1 and CTGF.39,59,60 For
example, we have recently demonstrated such a role for YAP−
TEAD-dependent regulation of CCN1 in the regulation of
vascular smooth muscle cell (VSMC) proliferation and
migration.39 We therefore tested whether CPD3 inhibited
the promoter activity of known TEAD target genes, CCN1 and
CTGF, in the HeLa transformed cell line and primary rat
VSMCs (RaVSMCs). Cells were transfected with plasmids
expressing bioluminescent ﬁreﬂy luciferase reporter genes
under the control of either the CCN1 or CTGF promoter
regions. Incubation with CPD3 for 6 h resulted in a strong and
signiﬁcant dose-dependent inhibition of CCN1- and CTGF-
luciferase reporter gene activities in both HeLa cells (Figure
3A) and RaVSMCs (Figure 3B). As both CCN1 and CTGF are
classical TEAD target genes, this is consistent with the
inhibition of TEAD activity by CPD3. Importantly, activity of
the TEAD-independent minimal TNT1 gene promoter, which
lacks TEAD-binding elements, was not inhibited by any
concentration of CPD3 tested, indicating that CPD3
selectively inhibits TEAD-dependent transcription and does
not nonspeciﬁcally reduce the transcription of TEAD-
independent genes. Furthermore, steady-state mRNA levels
of endogenous CCN1 and CTGF genes, which are known to be
involved in the promotion of cell proliferation and migration,
but not the TEAD-independent housekeeping gene 36B4, were
also signiﬁcantly inhibited by CPD3 (Supplement Figure 4).
CPD3 also dose-dependently inhibited cell proliferation
(detected by the incorporation of EdU into newly synthesized
DNA (Figure 3C,D)) and migration (detected by real-time
scratch wound assay), in both HeLa (Figure 3E) and
RaVSMCs (Figure 3F and Supplement Figure 5).
Functional Analysis of Compound 3 Fragments. We
tested three small molecular fragments of CPD3 for TEAD
inhibitory activity. CPD3.1 represents the planar aromatic ring
structure of CPD3, CPD3.2 is a piperazinyl propanediol
representing the mid-region of CPD3, and CPD3.3 represents
the terminal furyl group (Figure 4A). Dose−response analysis
demonstrated that CPD3 signiﬁcantly inhibited TEAD-
dependent NLUC secretion in HeLa at 60 μM with IC50 >
110 μM (Figure 4B) but did not aﬀect cell viability
(Supplement Figure 6) or have any direct inhibitory eﬀect
on NLUC enzymatic activity at any concentration tested
(Supplement Figure 7A). CPD3.1 also signiﬁcantly inhibited
TEAD-dependent NLUC secretion at 20 μM with IC50 = 70
μM (Figure 4C), without aﬀecting cell viability (Supplement
Figure 6) and without having any direct inhibitory eﬀect on
NLUC activity (Supplement Figure 7B). Although not strictly
applicable to this type of indirect reporter gene assay, the Hill
slopes for both CPD3 and CPD3.1 (Figure 4B,C) were close
to 1 (0.77 and 0.73, respectively). Although CPD3.1 appeared
Figure 2. BUDE docking pose for compound 3. (A) Surface plot of
TEAD1 (PDB:3kys) in blue with the YAP chain shown in yellow
(with a transparent surface render) and compound 3 structure (red)
binding pose. (B) Close up render of the TEAD1 hydrophobic pocket
showing the compound 3 binding pose. The YAP Phe95 side-chain is
depicted in yellow.
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to be a more potent inhibitor of TEAD activity in these cell-
based assays, this may simply reﬂect increased cell permeability
compared to CPD3. Neither CPD3.2 nor CPD3.3 had any
eﬀect on TEAD-NLUC activity (Figure 4D,E) or cell viability
(Supplement Figure 6). This suggests that the planar indole-
based aromatic ring structure of CPD3.1 represents the
functional YAP−TEAD inhibitory group. BUDE docking of
CPD3.1 (see PDB Data File) predicts that this compound
occupies the TEAD pocket in a similar pose to CPD3 (root-
mean-square deviation (RMSD) between corresponding atoms
is 2.42 Å) (Figure 5A,B). Binding of CPD3.1 to puriﬁed
recombinant TEAD protein was conﬁrmed by saturation
transfer diﬀerence (STD) NMR (Figure 6) and isothermal
titration calorimetry (Supplement Figure 8), which estimated
the binding aﬃnity to TEAD1 in the low micromolar range
(∼12 μM).
TEAD proteins (TEAD1−4) display a high degree of
sequence conservation in residues that create the hydrophobic
pocket that is essential for YAP binding.51 YAP proteins also
display a high degree of conservation in residues that interact
with this pocket.51 We therefore tested whether CPD3.1 was
able to inhibit YAP-induced activity of TEAD1, TEAD2,
TEAD3, and TEAD4. To quantify the eﬀect of CPD3.1 on the
activity of each individual TEAD paralog, while excluding
interference from endogenously expressed TEAD1−4 proteins,
we expressed each TEAD paralog (TEAD1−4) fused to the
yeast GAL4 DNA-binding domain. Cells were transfected with
the GAL4−TEAD expression vector together with a secreted
nanoluciferase reporter gene vector under control of a
promoter containing ﬁve GAL4 DNA-binding elements. This
system allows us to study the eﬀect of CPD3.1 on the activity
of each individual TEAD protein in isolation, without
interference from endogenously expressed transcription
factors. In addition, the cells were co-transfected with a YAP
expression vector to activate the GAL4−TEAD fusion-
dependent transcription (see Supplement Figure 9). Basal
activities of TEAD1, TEAD2, TEAD3, and TEAD4 were
inhibited by CPD3.1 (Figure 7A−D). This likely reﬂects the
Figure 3. Compound 3 inhibits TEAD target gene expression, cell proliferation, and cell migration. HeLa cells (A) and RaVSMCs (B) were
transfected with CCN1-LUC, CTGF-LUC or minimal promoter-LUC (minP-LUC) reporter plasmids and treated with indicated concentrations of
compound 3 for 6 h. Cell lysates were assayed for ﬁre-ﬂy luciferase activity (n = 3). HeLa cells (C) and RaVSMCs (D) were treated with indicated
concentrations of compound 3 for 18 h, followed by a 6 h labeling with 10 μM EdU (n = 4). HeLa cells (E) and RaVSMCs (F) were treated with
the indicated concentrations of compound 3 and migration quantiﬁed using a real-time IncuCyte scratch wound assay (n = 4). * = p < 0.05, ** = p
< 0.01, *** = p < 0.001.
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inhibition of TEAD activity driven by endogenous expression
of YAP. Activity of all four TEAD paralogs was stimulated by
YAP overexpression and this was signiﬁcantly inhibited by
CPD3.1 (Figure 7A−D). This suggests that the conservation
of residues forming the YAP binding TEAD pocket allows
CPD3.1 to inhibit YAP activation of all TEAD paralogs.
Dose−response analysis demonstrated that CPD3.1 inhibited
YAP-induced TEAD1 activity with IC50 = 40 μM (Figure 7E),
Figure 4. Functional analysis of compound 3 fragments. (A) Chemical structures of compound 3 and fragments of compound 3 (compound 3.1 −
3.3). HeLa cells stably expressing TEAD-NLUC were treated with indicated concentrations of compound 3 (n = 3) (B), compound 3.1 (n = 3)
(C), compound 3.2 (n = 3) (D), compound 3.3 (n = 3) (E) for 6 h. Secreted nano-luciferase activity was quantiﬁed in the cell conditioned media.
Figure 5. BUDE docking pose for compound 3.1. (A) Surface plot of TEAD1 (PDB:3kys) in blue with the YAP chain shown in yellow and
compound 3.1 structure binding pose (green). (B) Close up render of the TEAD1 hydrophobic pocket showing the compound 3.1 (green) and
compound 3 (red) binding pose. The YAP Phe95 side-chain is depicted in yellow.
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TEAD2 activity with IC50 = 33 μM (Figure 7F), TEAD3
activity with IC50 = 44 μM (Figure 7G), and TEAD4 activity
with IC50 = 36 μM (Figure 7H). Importantly, CPD3.1 did not
inhibit the basal activity of a TEAD-independent GAL4
reporter vector (Supplement Figure 10A). As a negative
control to test for any oﬀ-target eﬀects of CPD3.1, we used a
reporter gene vector for a diﬀerent transcription factor. For
this, we used a serum response factor (SRF) reporter gene
containing ﬁve serum response factor-binding elements instead
of TEAD-binding elements. The cells were co-transfected with
the SRF reporter gene together with a plasmid expressing
serum response factor (SRF) protein fused to the VP16
transcriptional activation domain of herpes simplex virus type I
(SRF−VP16). Expression of the SRF−VP16 fusion protein
strongly activates the SRF-dependent reporter gene, allowing
us to detect any inhibition of SRF activity. The SRF-dependent
reporter gene activity was not inhibited by CPD3.1, thus
providing more evidence of its selectivity for TEAD (Supple-
ment Figure 10B).
CPD3.1 Inhibits TEAD Target Gene Expression, Cell
Proliferation, and Cell Migration. Since the smaller
CPD3.1 fragment retains TEAD inhibitory activity, we next
tested whether CPD3.1 was able to inhibit TEAD target gene
expression, cell proliferation, and cell migration in HeLa and
RaVSMCs. Incubation of HeLa cells with CPD3.1 resulted in a
dose-dependent inhibition of CCN1- and CTGF-luciferase
reporter gene activities without aﬀecting expression from the
TEAD-independent minimal TNT1 promoter (Figure 8A),
consistent with speciﬁc inhibition of TEAD activity. CCN1 and
CTGF genes have previously been implicated in the regulation
of cell proliferation and migration.39 Consistent with this,
CPD3.1 also dose-dependently inhibited HeLa cell prolifer-
ation (Figure 8B), with EdU incorporation signiﬁcantly
inhibited at doses above 40 μM. CPD3.1 also signiﬁcantly
inhibited HeLa cell migration at 40, 60, and 80 μM (Figure
8C).
In RaVSMCs, CPD3.1 dose-dependently inhibited TEAD-
NLUC activity (Figure 9A; IC50 = 24 μM) and CCN1-LUC
(Figure 9B; EC50 = 48 μM) and CTGF-LUC (Figure 9C; EC50
= 58 μM) luciferase reporter gene activities. Moreover, the
expression of steady-state mRNA levels for known TEAD
target genes (CCN1, CTGF, PAI1, THBS, MAYDM, and
MYOC) was also signiﬁcantly inhibited by CPD3.1 (Figure
9D). Dose−response experiments demonstrated the inhibition
of THBS at 10 μM, CCN1 at 20 μM, and CTGF at 40 μM
(Supplement Figure 11). However, steady-state mRNA levels
of the TEAD-independent housekeeping genes PGK1, TBP,
GAPDH, and 36B4 were unaﬀected (Figure 9E), indicating
that CPD3.1 selectively inhibits TEAD-dependent target gene
expression and not simply by globally inhibiting transcription.
Western blotting of total cell lysates also demonstrated that
CPD3.1 inhibited the expression of CCN1 protein levels
(Figure 9F), conﬁrming that these inhibitory eﬀects translate
into a reduction in protein levels. Incubation of RaVSMC
(Figure 9G) or human VSMC (Figure 9H) with CPD3.1 for
18 h resulted in a dose-dependent inhibition of cell
proliferation, detected by EdU incorporation. The EC50 for
the inhibition of proliferation was 10 μM in RaVSMC and 1.5
Figure 6. Saturation transfer diﬀerence (STD) NMR analysis of compound 3.1 binding to TEAD1. Saturation-Transfer Diﬀerence (STD) NMR
spectra showing the binding of CPD3.1 to recombinant TEAD1. (A) reference 1H NMR spectra of a mixture of CPD3.1 and TEAD1. (B) and (C)
show the STD spectra of CPD3.1 in the absence and presence of TEAD1. The asterisk indicates buﬀer components or impurities in the sample.
The three spectra were recorded in PBS made up in 40% H2O/60% D2O acquired at 700 MHz. The concentration of CPD3.1 was 2 mM, whereas
the ﬁnal concentration of TEAD1 was approximately 20 μM.
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μM in HuVSMC. RaVSMC and HuVSMC migration was
similarly inhibited in a dose-dependent manner by 2, 10, and
20 μM CPD3.1 in RaVSMC (Figure 9I) and 0.25, 0.5, 2, and
10 μM in HuVSMC (Figure 9J). Importantly, CPD3.1 did not
inhibit the proliferation of MCF7 cells (Supplement Figure
12), which have previously been reported to exhibit YAP−
TEAD-independent growth.50
■ DISCUSSION AND CONCLUSIONS
Here, we report the discovery of a novel low-molecular-weight
YAP−TEAD protein−protein interaction inhibitor using an in
silico molecular docking screen of over 8 million druglike
compounds. We report that CPD3 blocks YAP interaction with
TEAD1 and inhibits TEAD activity, TEAD target gene
expression, cell proliferation, and cell migration. Analysis of
smaller fragment of CPD3 identiﬁed CPD3.1, which retains
TEAD inhibitory activity. This compound displays more
potent TEAD inhibitory activity in live cell assays, although
this may be due, at least in part, to improved cell permeability.
This study demonstrates that in silico molecular docking using
the BUDE algorithm is a fast and cost-eﬀective method for
screening very large numbers of druglike small molecules to
identify novel protein−protein interaction inhibitors. More
importantly, it demonstrates that the TEAD pocket, which is
responsible for YAP binding, is a viable drug target. The
molecules we describe are likely to represent valuable lead
compounds for the future development of potent TEAD
inhibitors.
Until recently, the computational cost, in terms of hardware,
time, and electricity consumption, of performing in silico
molecular docking to screen libraries of millions of compounds
was prohibitive. However, recent advances in modern
computer processing power mean that this approach is now
viable for augmenting or even replacing traditional screening
methods. Utilizing multiple graphics processing units in the
University of Bristol’s BlueCrystal supercomputer, we com-
Figure 7. Compound 3.1 inhibits TEAD1, TEAD2, TEAD3, and TEAD4 activities. HeLa cells were transfected with a 5×GAL4-secNLUC
reporter, together with expression vectors for GAL4-TEAD1, GAL4-TEAD2, GAL4-TEAD3 or GAL4-TEAD4 as indicated (A−H). In addition,
cells were also transfected with plasmids expressing YAP (A−H) as indicated. EMPTY indicated a control plasmid lacking a transgene. Cells were
treated with 100 μM (A−D) or indicated concentrations of compound 3.1 (E−H) and media were conditioned for 6 h. Secreted nano-luciferase
activity was quantiﬁed in the conditioned media. (n = 3) * = p < 0.05, *** = p < 0.001.
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pleted the initial screen of 8 million compounds within a few
weeks. Subsequent validation of the short-listed compounds
identiﬁed four compounds with TEAD inhibitory activity,
demonstrating the eﬃcacy of the BUDE algorithm. We focused
our attention on CPD3 because this compound inhibited
TEAD activity and disrupted YAP interaction. However, other
compounds identiﬁed by our screen were able to inhibit TEAD
activity without detectable eﬀects on YAP interaction,
suggesting that the occupation of the TEAD pocket by small
molecules may be able to disrupt TEAD function, even when
YAP remains bound. A similar disruption of TEAD function
has been proposed to explain the TEAD inhibitory activity of
ﬂufenamates.52 It is possible that these compounds induce
subtle conformational changes in the YAP−TEAD complex or
block important posttranslational modiﬁcations that are
important for TEAD function, such as palmitoylation.52,61
The docking pose for CPD3 predicts that the large planar
aromatic ring structure, present at one end of the molecule,
occupies the TEAD pocket and occludes the hydrophobic side
chains of YAP Met86, Ile91, and Phe95 previously demonstrated
to be essential for YAP interaction.51 Consistent with this, a
fragment of CPD3, termed CPD3.1 that is based only on this
aromatic ring structure, is predicted to bind the pocket in a
similar position and retains TEAD inhibitory activity. In
TEAD-dependent reporter gene assays, CPD3.1 was more
potent than the parental compound CPD3 with IC50 = 70 μM
compared to IC50 = 110 μM for CPD3. This may reﬂect
increased cell permeability, increased compound stability, or
increased aﬃnity for TEAD. Furthermore, using a GAL4
reporter system and GAL4 fusions of TEAD1, TEAD2,
TEAD3, and TEAD4, we demonstrated that CPD3.1 inhibited
YAP-induced activity of all four TEAD isoforms with a similar
potency (IC50 of 40, 33, 48, and 35 μM for TEAD1−4,
respectively), demonstrating its pan-TEAD inhibitory activity.
This likely reﬂects the high degree of sequence conservation in
amino acids that form this pocket in all four TEAD isoforms.
Importantly, CPD3.1 did not inhibit the activity of two TEAD-
independent promoters or the endogenous mRNA expression
of several TEAD-independent housekeeping genes, indicating
speciﬁc inhibition of TEAD-dependent transcription.
The current lack of detailed knowledge of the cellular
functions of each TEAD paralog means that it is unclear
whether therapeutically useful TEAD inhibitors will be needed
to target speciﬁc individual TEAD isoforms. Whether there is
suﬃcient chemical and structural diversity in the YAP binding
pocket to allow for paralog-selective inhibitors remains to be
determined. YAP residues, essential for TEAD binding, that
interact with this pocket are also conserved in TAZ, and the
TAZ−TEAD4 crystal structure62 indicates that TAZ can bind
in a similar manner to YAP. It is also important to consider the
wide-ranging biological functions of TEAD transcription
factors, which have been shown to regulate diverse cellular
functions, including osteoclastogenesis,63 myoblast diﬀer-
entiation,64 and cell fate decisions.65 This may suggest that
future pan-TEAD inhibiting therapies may be limited by
undesirable side eﬀects. However, this highlights the need for
more research to dissect the speciﬁc function of individual
TEAD proteins and the developments of TEAD isoform-
speciﬁc inhibitors.
In summary, we report the identiﬁcation of a novel YAP−
TEAD protein−protein interaction inhibitor that inhibits
TEAD activity, TEAD target gene expression, cell proliferation,
and cell migration. We also describe the active fragment of this
compound that retains all of these inhibitory properties. We
suggest that this compound may aid the development of future
lead compounds representing potent and selective TEAD
inhibitors. Such compounds should be useful for the
development of new therapies for the treatment of hyper-
proliferative cardiovascular diseases and patients who harbor
cancers with ampliﬁed or overexpressed YAP, TAZ, or TEAD
genes.
■ EXPERIMENTAL SECTION
BUDE in Silico Molecular Docking. In silico molecular docking
was performed using the Bristol University Docking Engine
(BUDE)56,57 to dock conformers generated from the ZINC database
into the YAP binding site of TEAD (3KYS.pdb). Brieﬂy, the BUDE
search area was deﬁned as a 15 × 15 × 15 Å3 grid centered on the
epsilon 2 carbon atom of the YAP phenylalanine 95 residues (see
Supplement Figure 1). Only TEAD1 atoms within 20 Å of this carbon
atom were included in the docking analysis. A library of >8 million
compounds, obtained from the clean, druglike subset of the ZINC8
database, was used for docking studies. Multiple conformers
(approximately 20 per compound) of these compounds were
generated using Confort (Certara Inc.), resulting in a library of
Figure 8. Compound 3.1 inhibits TEAD target gene expression, cell proliferation, and cell migration in HeLa cells. (A) HeLa cells were transfected
with CCN1-FUC, CTGF-LUC or minimal promoter-LUC (minP-LUC) reporter plasmids and treated with indicated concentrations of compound
3.1 for 6 hr. Cell lysates were assayed for ﬁre-ﬂy luciferase activity (n = 3). (B) HeLa were treated with indicated concentrations of compound 3.1
for 18 h, followed by 6 h labeling with 10 μM EdU (n = 4). HeLa cells were treated with the indicated concentrations of compound 3.1 and
migration quantiﬁed using a real time IncuCyte scratch wound assay (n = 4). * = p < 0.05, *** = p < 0.001.
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Figure 9. Compound 3.1 inhibits TEAD target gene expression, cell proliferation, and cell migration in RaVSMCs. RaVSMCs stably transduced
with TEAD-NLUC (A) or transiently transfected with CCN1-LUC or CTGF-LUC were treated with the indicated concentrations of compound 3.1
for 6 hr. Cell conditioned media (A) or cell lysates (B−C) were assayed for nanoluciferase or ﬁre-ﬂy luciferase activity, respectively. VSMC were
treated with 60 μM compound 3.1 for 6 h (n = 3). Total RNA was analyzed for mRNA levels of TEAD-target genes (D) or constitutive
housekeeping genes (E) by qRT-PCR. VSMC were treated with indicated concentrations of compound 3.1 for 16 hr (n = 4). Total cell lysates were
analyzed for CCN1 protein expression by Western blotting (F). RaVSMCs (G) or HuVSMC (H) were treated with indicated concentrations of
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approximately 160 million distinct structures that was docked into the
TEAD1 pocket that forms the YAP−TEAD interaction interface 3.51
Each conformer was docked using 20 000 randomly generated “poses”
within the search space and the free energy of binding between the
conformer and TEAD calculated. The 1000 poses with the lowest
energies were selected and randomly “mutated” with X, Y, and Z axis
translations and rotations to generate a new generation of 20 000
poses. Ten generations of this docking algorithm were performed,
resulting in an optimized docking pose for each conformer and a list
of all 160 million conformers ranked by predicted free energy of
binding. The top 100 000 ranked compound conformers with the
lowest binding energies were selected and docked with ﬁve
conformers of TEAD1. The top 1000 compound conformers with
the lowest binding energies for each TEAD conformer were selected,
and compound conformers that appeared in at least four of the list
were identiﬁed (Supplement Data File S1). This resulted in 3.85% of
compound conformers (representing 91 distinct compounds) being
shortlisted (Supplement Figure 1). Of these 91 compounds, only 38
(41.75%) were commercially available (Supplement Figure 2). These
38 compounds were manually curated for chemical diversity and 16
selected for testing. Shortlisted hits were screened for pan assay
interference compounds (PAINS) using the online PAINS ﬁlters at
http://zinc15.docking.org/patterns/home/ and http://www.cbligand.
org/PAINS/. Hit compounds passed both ﬁlters.
Modeling Methods. The TEAD/YAP complex crystal structure
(3KYS.pdb) was used as the basis for the 100 ns dynamics simulations
of the apo TEAD protein. The GROMACS 5.1.2.66 software suite
with the Amber99-SB-ILDN67 force ﬁeld was used to generate
multiple TEAD conformers. Five frames were chosen, representing
the greatest RMSD across the trajectory.
Molecular graphics manipulations and visualizations were per-
formed using VMD-1.9.1 and Chimera-1.10.2.68 Pdb2gmx was used
to prepare the assembly. Hydrogen atoms were added consistent with
pH 7. The system was surrounded by a box extending 2 nm from the
peptide (in each axis) and ﬁlled with TIP3P water. The random water
molecules were replaced by sodium and chloride ions to give a neutral
(uncharged overall) box and an ionic strength of 0.15 M. The system
was energy-minimized for 5000 steps prior to position-restrained and
subsequent unrestrained, molecular dynamics simulations.
Simulation Details. All simulations were performed as NPT
(standard state) ensembles at 310 K using periodic boundary
conditions. Short-range electrostatic and van der Waals interactions
were truncated at 1.4 nm, while long-range electrostatics were treated
with the particle mesh Ewald’s method and a long-range dispersion
correction applied. Pressure was controlled by the Parrinello−
Rahman barostat and temperature by the Nose−́Hoover thermostat.
The simulations were integrated with a leap-frog algorithm over a 2 fs
time step, constraining bond vibrations with the P-LINCS method.
Structures were saved every 0.1 ns for analysis and run over 100 ns.
Simulation data were accumulated on BlueCrystal, the University of
Bristol’s high-performance computing machine.
Compound Selection for Testing in Vitro. The output from
the initial BUDE docking process provided poses and predicted
binding energies for all conformers. These were analyzed and sorted
according to binding energy. The top 100 000 most favored binders
were redocked into multiple conformers of the TEAD protein. These
were again analyzed and ranked, and the compounds that had the best
predicted binding energies and that performed consistently across all
docks were selected for purchase (Supplement Table 1).
Compounds. Unless otherwise stated, all screening compounds
were purchased from Molport (Latvia). Compound 3.1 was
purchased from Fluorochem (U.K.). Compounds 3.2 and 3.3 were
purchased from Sigma-Aldrich (U.K.). All compounds were dissolved
in dimethyl sulfoxide at a concentration of either 10 or 20 mM.
Respective order numbers and ZINC IDs for all compounds are
described in Supplement Table 2. Commercially obtained test
compounds had >95% purity and were not puriﬁed further.
Compound purity was conﬁrmed by 1H NMR spectroscopy
(Supplement Figure 9).
Cell Culture. HeLa cells were purchased from the American
Tissue Culture Collection (ATCC) and cultured in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum, 100 U/mL penicillin, 100 U/mL streptomycin, and 2
mM L-glutamine. Vascular smooth muscle cells (VSMCs) were
isolated from the thoracic aortas of male Sprague-Dawley rats killed
by cervical dislocation in accordance with the Directive 2010/63/EU
of the European Parliament. Approval was granted by the University
of Bristol ethical review board. Cultures of rat aortic VSMCs
(RaVSMCs) were performed in 10% fetal calf serum/DMEM unless
otherwise stated.
In Vitro GST−TEAD−YAP Interaction Assays. The DNA
fragment encoding human TEAD1 (corresponding to residues 194−
411) was ampliﬁed by polymerase chain reaction (PCR) and cloned
into the BamH1 and EcoR1 sites of vector pGEX-6P1, in frame with
the terminal GST tag. GST−TEAD1 fusion protein expression was
induced in SoluBL21s Escherichia coli by culture at 25 °C in the
presence of 0.2 mM IPTG for 18 h. GST−TEAD1 protein was bound
to glutathione resin (GE Healthcare), and 25 μL of beads (containing
approximately 5 μg of GST−TEAD1) was used to aﬃnity-isolate
endogenous human YAP protein from HEK293 cell lysate by
incubation at 4 °C for 18 h in binding buﬀer (10 mM Tris pH 8.0,
150 mM NaCl, 10 mM MgCl2, 5% glycerol, 0.5% Triton-X-100) in
the presence of 200 μM of the indicated compound. Bound proteins
were eluted by boiling in Laemmli sample buﬀer and YAP and GST−
TEAD levels quantiﬁed by Western blotting with an anti-YAP
antibody (Cell Signaling; #4912) and an anti-GST antibody (Cell
Signaling; #5475S).
Co-immunoprecipitation and YAP−TEAD Interaction As-
says. HeLa cells were transiently transfected with either pRK5-myc-
TEAD1 (Addgene #33109) or pEGFP-C3-YAP1 (Addgene #17843).
These plasmids express human TEAD1 protein fused to the myc-
epitope-tag amino acid sequence (amino acids: EQKLISEEDL) or
YAP1 fused to enhanced green ﬂuorescent protein, respectively.
Cytosolic extracts were prepared in 10 mM Tris pH 7.6, 10 mM KCl,
0.5 mM ethylenediaminetetraacetic acid (EDTA), and 0.2% NP-40.
Nuclei were pelleted and extracted in half volume of 10 mM Tris pH
7.6, 10 mM KCl, 450 mM NaCl, 0.5 mM dithiothreitol, and 0.5 mM
EDTA and pooled with the cytosolic extracts. Myc-TEAD-containing
extracts were incubated on ice for 30 min with 200 μM CPD3. An
equal volume of GFP−YAP-containing lysate was added and
incubated for a further 30 min on ice. GFP−YAP or myc-TEAD1
was immunoprecipitated, as indicated, using GFP-Trap or Myc-Trap
beads (Chromotek), respectively. Following washing, immunopreci-
pitated proteins were eluted by boiling in sodium dodecyl sulfate
(SDS) buﬀer (50 mM Tris pH 6.8, 20% glycerol, 2% SDS) and
analyzed by Western blotting.
YAP−TEAD interaction assays were performed in 96-well protein-
G-coated plates (Pierce) by capturing myc-TEAD1 from cell lysates
of HeLa cells transiently transfected with pRK5-myc-TEAD1 plasmid
with an anti-myc tag antibody (Thermo Fisher Scientiﬁc; clone
9E10). Plates with immobilized myc-TEAD were pretreated with
indicated concentrations of compound in phosphate-buﬀered saline
(PBS) for 1 h at 4 °C before co-incubation with lysate from HeLa
cells transiently transfected with a plasmid expressing YAP−
nanoluciferase fusion protein (YAP−NL). Following four washes in
PBS, bound YAP−NL was detected and quantiﬁed by incubation with
NanoGlo assay buﬀer (Figure 1G).
Figure 9. continued
compound 3.1 for 18 h followed by labeling in 10 μM EdU for a further 6 h (n = 4). RaVSMCs (I) or HuVSMC (J) were treated with indicated
concentrations of compound 3.1 and cell migration quantiﬁed using IncuCyte real time migration assay (n = 4).
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Reporter Gene Activity Assays. Compounds were initially
screened for ability to inhibit TEAD-dependent transcriptional
activity in HeLa cells transduced with a lentiviral vector expressing
secreted nanoluciferase under the control of multimerized TEAD
consensus elements (5′-CACATTCCA-3′). 8xTEAD NanoLuc was
generated by cloning the 8xTEAD promoter from the 8xTEAD-Luc
plasmid (Addgene #34615) into the pENTR gateway entry vector
(Promega). This was then recombined into pLNT-sec-Nluc-2A-eGFP
destination vector (supplied by Tristan McKay; University of
Manchester). Lentiviruses were generated by Viafect-mediated co-
transfection of pLNT8x-TEAD-sec-Nluc-2A-eGFP, Δ8.9, and VSV-G
vectors into HEK293T cells (ATCC), and lentiviral-containing
culture supernatants were used to infect HeLa cells in the presence
of 6 μg/mL polybrene. For compound screening, 8xTEAD NanoLuc-
transduced HeLa cells were seeded at 2 × 104 cells/well in 96-well
plates. After 48 h, the cells were washed in PBS and incubated with
test compounds at the indicated concentrations for 2 h. The cells were
washed again in PBS and incubated with the compound for a further 4
h. Conditioned culture medium (50 μL) was assayed for secreted
nanoluciferase activity using NanoGlo activity assays kit (Promega)
and a Glomax Discover luminometer.
TNT1-minP reporter containing the Troponin-T minimal
promoter was generated by digesting 8xGTIIC-luciferase plasmid
(Addgene #34615) with Kpn1 and BglII to remove the TEAD
elements, followed by blunt end re-ligation. A 2.177 kb fragment of
the human CCN1 promoter containing two proximal TEAD elements
(Hg19;chr1:86044316−chr1:86046493) was described previously39
and cloned into pGL4-luciferase (Promega). The proximal promoter
regions of the CTGF (Hg19;chr6:132272455−132272687) promoter,
containing a consensus TEAD-binding element, was ampliﬁed by
PCR from human genomic DNA and cloned into the Kpn1 and Nhe1
sites of pGL4-luciferase. The cells were transfected with ﬁreﬂy
luciferase reporter plasmids using a Nuceofector 1.5 (Lonza). Cell
lysates were assayed for luciferase activity using the luciferase assay
system (Promega). GAL4-Nano-luciferase plasmid (GLA4-NLUC)
was created by subcloning the 5xGAL4 binding elements from
plasmid pG5E1b-LUC (a gift from Ugo Moens, University of
Tromsø, Norway) into the Nhe1 and Xho1 sites of pNL3.3[sec-Nluc/
minP] (Promega). Plasmids expressing GAL4 fusions of TEAD1
(#33108), TEAD2 (#33107), TEAD3 (#33106), and TEAD4
(#33105) and FLAG-YAP (#18881) were obtained from Addgene.
Cell Viability Assay. Cell viability was quantiﬁed using the live/
dead viability/cytotoxicity assay standard protocol (Invitrogen).
Maximum cell death was quantiﬁed by incubating cells for 10 min
with 0.1% Triton-X, followed by incubation with 0.4 μM ethidium
homodimer-1 for an additional 10 min. Fluorescence was measured
using a GloMax Discover multiplate reader (Promega).
Proliferation and Real-Time Scratch Wound Migration
Assays. Cell proliferation was measured using the Click-iT EdU
488 assay (Sigma-Aldrich). Brieﬂy, the cells were treated with
indicated concentrations of compounds for 24 h with the last 4 h
being in the presence of 10 μM EdU. The cells were ﬁxed in 4%
formaldehyde and stained for EdU incorporation, following the kit’s
standard protocol. The cells were counterstained with Hoechst 33342
nucleic acid for 20 min. Fluorescent images of at least three ﬁelds of
view per well were counted using ImageJ software. Real-time analysis
of cell migration was performed using an IncuCyte ZOOM live cell
imaging system (Essen BioScience) according to the manufacturer’s
instructions. Brieﬂy, the cells were seeded (1.2 × 104 cells/well for
HeLa cells, 1.5 × 104 cells/well for RaVSMCs, and 1 × 104 cells/well)
into ImageLock 96-well plates. After 36 h, the cells were pretreated
overnight with indicated concentrations of compounds. The wells
were scratched using a WoundMaker tool, and the media were
replaced containing test compounds. Phase contrast images of cell
migration into the wounded area were acquired hourly for 24 h.
Relative wound conﬂuence was calculated using the Cell Migration
Image analysis module of the IncuCyte ZOOM software.
Quantitative reverse transcription (RT)-PCR: quantiﬁcation of
mRNA was performed by RT-qPCR, as described previously.39 Total
RNA was extracted using Ambion PureLink kits (Thermo Fisher) and
reverse-transcribed using QuantiTect RT kit (Qiagen) and random
primers. Quantitative PCR was performed using Roche SYBR Green
using a Qiagen Roto-GeneRotor-Gene Q PCR machine (20
seconds@95 °C; 20 seconds @62 °C; 20 seconds@72 °C). Data
were normalized to nonstimulated controls. Primer sequences are
described in Supplement Table 2.
Western Blotting. Extracted samples were separated by 4−12%
SDS-polyacrylamide gel electrophoresis (Bio-Rad) and transferred to
poly(vinylidene diﬂuoride) membranes (GE Healthcare). Membranes
were blocked in 5% low-fat milk in 10 mM Tris pH 7.6, 150 mM
NaCl, 0.2% Tween. Antibodies YAP (1:1000, Cell Signaling; 4912S),
CCN1 (1:1000, R&D Systems; AF6009), GAPDH (1:10 000,
Millipore; MAB374), and GST (1:1000, Cell Signaling; 5475S), for
GST-tagged TEAD detection, were incubated overnight in 5% bovine
serum albumin in 10 mM Tris pH 7.6, 150 mM NaCl, 0.2% Tween,
followed by probing with a relevant secondary antibody and
developed using ChemiDoc-MP imaging system (Bio-Rad).
Saturation Transfer Diﬀusion Nuclear Magnetic Resonance
(STD NMR) Analysis. Binding of compounds to human TEAD was
performed using STD NMR analysis. Brieﬂy, TEAD1 protein
(residues 194−411) was prepared by solution cleavage of the GST
tag from recombinant GST−TEAD1 (194−411). GST−TEAD1
protein was eluted from glutathione beads by 40 mM reduced
glutathione. GST tag was removed by incubation with PreScission
protease (Sigma-Aldrich) at 4 °C for 18 h. Glutathione was removed
by dialysis against 1000 volumes of 1× PBS at 4 °C for 4 h. Free GST
protein was removed by incubation with glutathione resin. All NMR
spectroscopy experiments were performed on a Bruker Avance III HD
700 MHz spectrometer equipped with a 1.7 mm inverse triple-
resonance microcryocoil probe. NMR samples were prepared in 40
μL with PBS pH 7.4 in 60% D2O (uncorrected for D2O). TEAD (20
mM) was used with a ﬁnal concentration of 2 mM compound. For the
STD experiments, the standard Bruker stddiﬀesgp.3 pulse sequence
was used with a saturation time of 7 s and a spectral width of 15.9
ppm with eight scans. The on-resonance frequency was set to 0.85
ppm, while the oﬀ-resonance frequency was set to −28 ppm.
Appropriate blank experiments, in the absence of protein or ligand,
were performed to test the lack of direct saturation to the ligand
protons.
Statistical Analysis. Unless otherwise stated, data are presented
as mean ± standard error and analyzed by one-way analysis of
variance with Dunnett’s multiple comparison test for multiple
comparisons. * indicates p < 0.05, ** indicates p < 0.01, and ***
indicates p < 0.001.
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